CytoGenix, Inc. Announces Expansion of Its Advisory Board

NEW BRAUNFELS, Texas--(BUSINESS WIRE)--CytoGenix, Inc. (Pink sheets: CYGX) announced today that it has expanded its Advisory Board.

“With the founding of BioEnergy and the expansion of the Advisory Board, we are embarking on a multistage plan that we believe will result in a diversified company capable of entering new, global, revenue generating markets.”

Stephen Udem, PhD, MD: Dr. Udem is an internationally recognized virologist and vaccinologist who previously served as Vice President of Wyeth Vaccines Research and a member of the Wyeth Vaccine Business Unit's Senior Management. Dr. Udem has served as Chief Scientific Officer and Senior Vice President of Vaccine Development of the International AIDS Vaccine Initiative and founded his own Vaccine R&D consultant/advisor practice. Prior to joining industry, Dr. Udem held senior academic positions at the Albert Einstein College of Medicine and the New Jersey Medical School. He received his undergraduate degree from the City College of New York and his Ph.D. and M.D. from the Albert Einstein College of Medicine.

Peter Glazer, MD, PhD. Dr. Glazer is the Chairman of the Department of Therapeutic Radiology, the Robert E. Hunter Professor of Radiology, and Professor of Therapeutic Radiology and Genetics at Yale University School of Medicine. Dr. Glazer holds academic degrees from Harvard (BA), Oxford (MS), Yale (Ph.D.) and a Medical Degree from Yale University School of Medicine. His research interests include gene targeting and gene therapy, genetic instability in cancer, mutagenesis, and DNA repair.

Sergio Rosini, PhD. In 2006, Dr. Rosini retired from Abiogen Pharma SpA where he held the position of Director of R&D from 1998 to 2006. Prior to Abiogen, Dr. Rosini was the Director of R & D of Instituto Gentili from 1973 to 1998. Over his long and productive career, Dr. Rosini has developed over 25 products across multiple pharmaceutical categories. In November 2004, Dr. Rosini was the first Italian scientist to receive the prestigious Galeno Award in recognition of his long and distinguished scientific career.

Rick Barry: Rick is one of the most celebrated players in NBA history. Following his college career at University of Miami (FL), where he received his BBA Marketing, Rick was drafted third in the first round of the NBA draft. In his first year he was named Rookie of the Year and selected for the NBA All-Pro First Team. Upon retiring from the NBA Rick continued his broadcasting career and embarked on a successful business career where he was involved in multiple business ventures in the marketing, financial, and recreational sports industries. In addition to his own companies, Rick has been helping companies in their domestic business ventures, as well as in their global expansion programs. Currently Rick is a Senior Partner at N. S. Lachman & Co. a private equity firm and M&A advisory group.

Lex Cowsert, CytoGenix’s CEO, stated, “With the founding of BioEnergy and the expansion of the Advisory Board, we are embarking on a multistage plan that we believe will result in a diversified company capable of entering new, global, revenue generating markets.”

CytoGenix, Inc.

CytoGenix is a Nevada corporation traded under the symbol CYGX.PK. CytoGenix is a biotechnology company developing biotechnology derived products for vaccines and therapeutic applications for human, agricultural and veterinary markets. As such, CytoGenix has access to a broad range of biological expertise that can be leveraged to identify, evaluate, develop and commercialize biologically based technologies for energy production.

Safe Harbor Statement

The information contained in this news release, other than historical information, consists of forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. These statements may involve risks and uncertainties that could cause actual results to differ materially from those described in such statements. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. Important factors, including general economic conditions, spending levels and other factors could cause actual results to differ materially from the Company's expectations.